Search

Displaying results 1581 - 1590 of 10000 in total
  1. Drug

    Rosin

    go.drugbank.com/drugs/DB11165
    Approved

    In the pharmaceuticals, rosin is used in film forming and coating tablets and enterically administered agents, as well as forming microcapsules and nanoparticles. … Rosin has shown to mediate antibacterial actions on Gram-positive bacterial species [A27267].

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Bordetella pertussis toxoid antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14388
    ApprovedInvestigational

    Bordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.

    Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Repevax Injektionssuspension in einer Fertigspritze
  3. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394]

  4. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.

  5. Drug

    Tegafur

    go.drugbank.com/drugs/DB09256
    ApprovedInvestigational

    It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327]. … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the

    International brands: ESUEEW AN T
  6. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular

  7. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    The defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. … Foreskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various indications.

  8. Drug

    Temsirolimus

    go.drugbank.com/drugs/DB06287
    ApprovedInvestigational

    Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007. … Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel.

  9. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    from the market in 1997. … [A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal

  10. Drug

    Flavoxate

    go.drugbank.com/drugs/DB01148
    Approved

    A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. … It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]